株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗てんかん薬市場の分析・予測:米国・英国・フランスなど

Epilepsy Drugs Market by Country (US, UK, France, etc), Drugs (Vimpat, Keppra, Sabril, Onfi, etc), Treatment Drugs Generation (First, Second, Third), Companies & Forecast

発行 Renub Research 商品コード 781814
出版日 ページ情報 英文 103 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.85円で換算しております。
Back to Top
抗てんかん薬市場の分析・予測:米国・英国・フランスなど Epilepsy Drugs Market by Country (US, UK, France, etc), Drugs (Vimpat, Keppra, Sabril, Onfi, etc), Treatment Drugs Generation (First, Second, Third), Companies & Forecast
出版日: 2019年02月01日 ページ情報: 英文 103 Pages
概要

世界の抗てんかん薬の市場は2025年には90億米ドルを超える規模に成長すると予測されています。

当レポートでは、世界の抗てんかん薬の市場を調査し、市場および製品の概要、市場規模の推移と予測、国・薬剤カテゴリー・薬剤別の内訳、市場シェア、市場成長への各種影響因子の分析、主要企業のプロファイル・取り組みなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の抗てんかん薬市場の分析・予測

第5章 抗てんかん薬市場:市場シェアの推移・予測

  • 国別
  • 薬剤カテゴリー別
  • 薬剤別

第6章 抗てんかん薬市場の分析・予測:国別

  • 米国
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • スぺイン
  • インド
  • 中国
  • 日本

第7章 抗てんかん薬市場の分析・予測:薬剤カテゴリー別

  • 第1世代
  • 第2世代
  • 第3世代

第8章 抗てんかん薬市場の分析・予測:薬剤別

  • Vimpat (ラコサミド)
  • Keppra (レベチラセタム)
  • Sabril (ビガバトリン)
  • Onfi (クロバザム)
  • Fycompa
  • Briviact (ブリバラセタム )
  • Epidiolex
  • Cenobamate (YKP3089)

第9章 成長推進因子

第10章 課題

第11章 エーザイ

  • 企業概要
  • イニチアチブ・取り組み
  • 財務分析

第12章 UCB Inc.

  • 企業概要
  • イニチアチブ・取り組み
  • 財務分析

第13章 H. Lundbeck A/S

  • 企業概要
  • イニチアチブ・取り組み
  • 財務分析

第14章 GW Pharmaceuticals Plc.

  • 企業概要
  • イニチアチブ・取り組み
  • 財務分析
図表

List of Figures:

  • Figure 4-1: Global - Epilepsy Drugs Market (Million US$), 2013 - 2018
  • Figure 4-2: Global - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
  • Figure 5-1: Global - Epilepsy Drugs Market Country Share (Percent), 2013 - 2018
  • Figure 5-2: Global - Forecast for Epilepsy Drugs Market Country Share (Percent), 2019 - 2025
  • Figure 5-3: Global - Epilepsy Drugs Category Market Share (Percent), 2013 - 2018
  • Figure 5-4: Global - Forecast for Epilepsy Drugs Category Market Share (Percent), 2019 - 2025
  • Figure 5-5: Global - Epilepsy Drugs Market Share (Percent), 2013 - 2018
  • Figure 5-6: Global - Forecast for Epilepsy Drugs Market Share (Percent), 2019 - 2025
  • Figure 6-1: United States - Epilepsy Drugs Market (Million US$), 2013 - 2018
  • Figure 6-2: United States - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
  • Figure 6-3: United Kingdom - Epilepsy Drugs Market (Million US$), 2013 - 2018
  • Figure 6-4: United Kingdom - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
  • Figure 6-5: France - Epilepsy Drugs Market (Million US$), 2013 - 2018
  • Figure 6-6: France - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
  • Figure 6-7: Germany - Epilepsy Drugs Market (Million US$), 2013 - 2018
  • Figure 6-8: Germany - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
  • Figure 6-9: Italy - Epilepsy Drugs Market (Million US$), 2013 - 2018
  • Figure 6-10: Italy - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
  • Figure 6-11: Spain - Epilepsy Drugs Market (Million US$), 2013 - 2018
  • Figure 6-12: Spain - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
  • Figure 6-13: India - Epilepsy Drugs Market (Million US$), 2013 - 2018
  • Figure 6-14: India - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
  • Figure 6-15: China - Epilepsy Drugs Market (Million US$), 2013 - 2018
  • Figure 6-16: China - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
  • Figure 6-17: Japan - Epilepsy Drugs Market (Million US$), 2013 - 2018
  • Figure 6-18: Japan - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
  • Figure 7-1: Global - First Generation Epilepsy Drugs Market (Million US$), 2013 - 2018
  • Figure 7-2: Global - Forecast for First Generation Epilepsy Drugs Market (Million US$), 2019 - 2025
  • Figure 7-3: Global - Second Generation Epilepsy Drugs Market (Million US$), 2013 - 2018
  • Figure 7-4: Global - Forecast for Second Generation Epilepsy Drugs Market (Million US$), 2019 - 2025
  • Figure 7-5: Global - Third Generation Epilepsy Drugs Market (Million US$), 2013 - 2018
  • Figure 7-6: Global - Forecast for Third Generation Epilepsy Drugs Market (Million US$), 2019 - 2025
  • Figure 8-1: Global Epilepsy Drugs Market - Vimpat (Lacosamide) Sales (Million US$), 2013 - 2018
  • Figure 8-2: Global Epilepsy Drugs Market - Forecast for Vimpat (Lacosamide) Sales (Million US$), 2019 - 2025
  • Figure 8-3: Global Epilepsy Drugs Market - Keppra (Levetiracetam) Sales (Million US$), 2013 - 2018
  • Figure 8-4: Global Epilepsy Drugs Market - Forecast for Keppra (Levetiracetam) Sales (Million US$), 2019 - 2025
  • Figure 8-5: Global Epilepsy Drugs Market - Sabril (Vigabatrin) Sales (Million US$), 2013 - 2018
  • Figure 8-6: Global Epilepsy Drugs Market - Forecast for Sabril (Vigabatrin) Sales (Million US$), 2019 - 2025
  • Figure 8-7: Global Epilepsy Drugs Market - Onfi (Clobazam) Sales (Million US$), 2013 - 2018
  • Figure 8-8: Global Epilepsy Drugs Market - Forecast for Onfi (Clobazam) Sales (Million US$), 2019 - 2025
  • Figure 8-9: Global Epilepsy Drugs Market - Fycompa Sales (Million US$), 2015 - 2018
  • Figure 8-10: Global Epilepsy Drugs Market - Forecast for Fycompa Sales (Million US$), 2019 - 2025
  • Figure 8-11: Global Epilepsy Drugs Market - Briviact (Brivaracetam) Sales (Million US$), 2016 - 2018
  • Figure 8-12: Global Epilepsy Drugs Market - Forecast for Briviact (Brivaracetam) Sales (Million US$), 2019 - 2025
  • Figure 8-13: Global Epilepsy Drugs Market - Present & Forecast for Epidiolex Sales (Million US$), 2018 - 2025
  • Figure 8-14: Global Epilepsy Drugs Market - Forecast for Cenobamate (YKP3089) Sales (Million US$), 2019 - 2025
  • Figure 9-1: Global - Epilepsy Therapeutics Studies (Number), November 2018
  • Figure 11-1: Eisai Co., Ltd - Global Sales (Million US$), 2013 - 2018
  • Figure 11-2: Eisai Co., Ltd - Forecast for Global Sales (Million US$), 2019 - 2025
  • Figure 12-1: UCB Inc. - Global Sales (Million US$), 2013 - 2018
  • Figure 12-2: UCB Inc. - Forecast for Global Sales (Million US$), 2019 - 2025
  • Figure 13-1: Lundbeck - Global Sales (Million US$), 2013 - 2018
  • Figure 13-2: Lundbeck - Forecast for Global Sales (Million US$), 2019 - 2025
  • Figure 14-1: GW Pharmaceuticals - Global Revenue (Million US$), 2013 - 2018
  • Figure 14-2: GW Pharmaceuticals - Forecast for Global Revenue (Million US$), 2019 - 2025

N/A

目次

Epilepsy is a chronic disease in which patient's brain activities become abnormal due to seizures. Seizure is an unexpected rush of electrical activity in the brain. Seizure is categorized by two types - generalized seizures and focal or partial seizures. Generalized seizures affect the whole brain whereas focal or partial seizures affect just one part of the brain. Global epilepsy drugs market is expected to cross US$ 9 Billion landmark by 2025.

Epilepsy can develop in both males and females of all races, ethnic backgrounds and ages. It affects around 65 Million people globally. United States has around 3.4 Million epilepsy patients; among them around 470 Thousands are children. Epilepsy prevalence varies across various parts of the world. At present, nearly one-third of the total patients are suffering from uncontrollable seizures and are not able to get treatment because no available treatment works for them.

The factors that are driving the global Epilepsy drug market are increasing epilepsy prevalence, growing patient awareness programs, government funding and drugs reimbursement options in European & American countries. Recently, anti-epilepsy drugs Epidiolex approvals for pediatric epilepsies, namely Lennox-Gastaut syndrome and Dravet syndrome in United States will also help in the growth of Epilepsy drug market during the forecast period as well.

Renub Research report titled "Epilepsy Drugs Market by Country (United States, United Kingdom, France, Germany, Italy, Spain, India, China, Japan), Drugs [(Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089)], Treatment Drugs Generation (First, Second, Third), Company (Eisai Co., Ltd, UCB Inc., H. Lundbeck A/S, GW Pharmaceuticals Plc.) & Forecast" provides a complete analysis of Global Epilepsy Drugs Market. This report also covers all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.

By Country - United States is Dominating Global Epilepsy Drugs Market>

The report studies the market of the following countries: United States, United Kingdom, France, Germany, Italy, Spain, India, China and Japan. United States is dominating global epilepsy drugs market. Its share is expected to grow in the years to come due to better healthcare support system, growing awareness and increasing per capita healthcare expenditure.

By Drugs - Vimpat (Lacosamide), Keppra (Levetiracetam) and Epidiolex are playing a significant role>

The report studies the market of the following drugs: Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089). At present, Vimpat (Lacosamide) and Keppra (Levetiracetam) are playing the significant role for the epilepsy treatment. Epidiolex has a bright future ahead.

By Drugs Category - Second and Third Generation Plays the Significant Role>

In this report, we have categorized the epilepsy drugs market into three generation; First Generation, Second Generation, Third Generation. It is anticipated that second and third generation plays the significant role in the global epilepsy drugs market during the forecast period of 2019-2025.

Company Analysis

Eisai Co., Ltd, UCB Inc., H. Lundbeck A/S and GW Pharmaceuticals Plc. are some of the top companies that deal efficiently in epilepsy business globally. These companies have been studied thoroughly in the report.

Countries covered in this report are:

  • United States
  • United Kingdom
  • France
  • Germany
  • Italy
  • Spain
  • India
  • China
  • Japan

Epilepsy Drugs Category - By Generation

  • First Generation
  • Second Generation
  • Third Generation

Drugs covered in this report are:

  • Vimpat (Lacosamide)
  • Keppra (Levetiracetam)
  • Sabril (Vigabatrin)
  • Onfi (Clobazam)
  • Fycompa
  • Briviact (Brivaracetam)
  • Epidiolex
  • Cenobamate (YKP3089)

Companies covered in this report are:

  • Eisai Co., Ltd
  • UCB Inc.
  • H. Lundbeck A/S
  • GW Pharmaceuticals Plc.

Table of Contents

1. Introduction

  • 1.1 Market Definition
  • 1.2 Currency Conversion

2. Research Methodology

3. Executive Summary

4. Global Epilepsy Drugs Market (2013 - 2025)

5. Market Share - Global Epilepsy Drugs (2013 - 2025)

  • 5.1 By Country
  • 5.2 By Drugs Category
  • 5.3 By Drugs

6. Country - Global Epilepsy Drugs Market Analysis (2013 - 2025)

  • 6.1 United States
  • 6.2 United Kingdom
  • 6.3 France
  • 6.4 Germany
  • 6.5 Italy
  • 6.6 Spain
  • 6.7 India
  • 6.8 China
  • 6.9 Japan

7. By Drugs Category - Global Epilepsy Drugs Market Analysis (2013 - 2025)

  • 7.1 First Generation
  • 7.2 Second Generation
  • 7.3 Third Generation

8. By Drugs - Global Epilepsy Drugs Market Analysis (2013 - 2025)

  • 8.1 Vimpat (Lacosamide)
  • 8.2 Keppra (Levetiracetam)
  • 8.3 Sabril (Vigabatrin)
  • 8.4 Onfi (Clobazam)
  • 8.5 Fycompa
  • 8.6 Briviact (Brivaracetam)
  • 8.7 Epidiolex
  • 8.8 Cenobamate (YKP3089)

9. Growth Drivers

  • 9.1 Growing Awareness Programs Worldwide
  • 9.2 Presence of Promising Pipeline for Epilepsy Therapeutics

10. Challenges

  • 10.1 New Restrictions on Epilepsy Drug
  • 10.2 High Cost of Antiepileptic Drugs

11. Eisai Co., Ltd.

  • 11.1 Company Overview
  • 11.2 Initiatives/Activities
    • 11.2.1 Point 1
    • 11.2.2 Point 2
    • 11.2.3 Point 3
  • 11.3 Financial Insight

12. UCB Inc.

  • 12.1 Company Overview
  • 12.2 Initiatives/Activities
    • 12.2.1 Point 1
    • 12.2.2 Point 2
    • 12.2.3 Point 3
    • 12.2.4 Point 4
  • 12.3 Financial Insight

13. H. Lundbeck A/S

  • 13.1 Company Overview
  • 13.2 Initiatives/Activities
    • 13.2.1 Point 1
    • 13.2.2 Point 2
    • 13.2.3 Point 3
  • 13.3 Financial Insight

14. GW Pharmaceuticals Plc.

  • 14.1 Company Overview
  • 14.2 Initiatives/Activities
    • 14.2.1 Point 1
    • 14.2.2 Point 2
  • 14.3 Financial Insight
Back to Top